Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Nov 2;3(11):e2022906.
doi: 10.1001/jamanetworkopen.2020.22906.

Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers

Kiyofumi Shimoji  1 , Takeshi Masuda  1 , Kakuhiro Yamaguchi  1 , Shinjiro Sakamoto  1 , Yasushi Horimasu  1 , Taku Nakashima  1 , Shintaro Miyamoto  1 , Hiroshi Iwamoto  1 , Kazunori Fujitaka  1 , Hironobu Hamada  1 , Sachio Takeno  2 , Michihiro Hide  3 , Jun Teishima  4 , Hideki Ohdan  5 , Noboru Hattori  1
Affiliations
Comparative Study

Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers

Kiyofumi Shimoji et al. JAMA Netw Open. .

Abstract

Importance: Immune checkpoint inhibitor-induced interstitial lung disease (ICI-ILD) is clinically serious and life-threatening. Preexisting interstitial lung abnormalities have been shown to be risk factors for ICI-ILD in patients with lung cancer.

Objective: To evaluate whether interstitial lung abnormalities are associated with ICI-ILD in patients with nonlung cancers.

Design, setting, and participants: This cohort study was conducted between December 2015 and May 2019 at Hiroshima University Hospital. A total of 199 consecutive patients with head and neck cancer, malignant melanoma, oral cavity cancer, urological cancer, and gastrointestinal cancer who received anti-programmed cell death 1 (PD-1) antibody monotherapy were included. Data analysis was conducted from December 2015 to May 2019.

Main outcomes and measures: The associations between potential risk factors and the development of ICI-ILD were examined. Information on patient characteristics before antibody administration, including chest computed tomography findings, was obtained. The diagnosis of ICI-ILD was defined as abnormal computed tomography shadows occurring during treatment with anti-PD-1 antibodies.

Results: A total of 199 patients were enrolled in the study. The median (range) age was 66 (20-93) years, and most patients (133 [66.8%]) were men. Nineteen patients (9.5%) developed ICI-ILD. There was no significant difference in the baseline characteristics between patients with and without ICI-ILD. The logistic regression analyses revealed that interstitial lung abnormalities were associated with increased risk of ICI-ILD (odds ratio, 6.29; 95% CI, 2.34-16.92; P < .001), and ground glass attenuation in interstitial lung abnormalities was an independently associated risk factor (odds ratio, 4.05; 95% CI, 1.29-12.71; P = .01).

Conclusions and relevance: In this cohort study, preexisting interstitial lung abnormalities, including ground glass attenuation, were risk factors associated with ICI-ILD in patients with nonlung cancers. This observation is consistent with previously reported findings in patients with lung cancer. Therefore, we should pay more attention to the development of ICI-ILD in patients with interstitial lung abnormalities, regardless of cancer type.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Hattori reported receiving research funding from Ono Pharmaceutical, Chugai Pharmaceutical, and AstraZeneca. Dr Masuda reported receiving personal fees from Hugai Pharmaceutical and personal fees from Ono Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, and Kyowa Kirin outside the submitted work. Dr Sakamoto reported receiving personal fees from Ono Pharmaceutical and Eli Lilly and Co Japan during the conduct of the study. Dr Hide reported receiving grants from Ono Pharmaceutical during the conduct of the study and receiving personal fees from MSD outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Computed Tomography Images of Interstitial Lung Abnormalities
See this image and copyright information in PMC

References

    1. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311-319. doi: 10.1056/NEJMoa1411087 - DOI - PMC - PubMed
    1. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867. doi: 10.1056/NEJMoa1602252 - DOI - PMC - PubMed
    1. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5 - DOI - PubMed
    1. Motzer RJ, Escudier B, McDermott DF, et al. ; CheckMate 025 Investigators . Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813. doi: 10.1056/NEJMoa1510665 - DOI - PMC - PubMed
    1. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330. doi: 10.1056/NEJMoa1412082 - DOI - PubMed

Publication types

MeSH terms

Substances